glp-1 class action lawsuit Ozempic – July 2026 Update glp-1 nausea class action in

[DOI] [PubMed] [Google Scholar] 76.Tamayo-Trujillo R., Ruiz-Pozo V.A., Cadena-Ullauri S., Guevara-Ramrez P., Paz-Cruz E., Zambrano-Villacres R., Simancas-Racines D., Zambrano A.K

the STEP 5 trial represents the most extensive study on the use of semaglutide for weight management to date

A second MDL involves sudden vision changes, optic nerve damage, loss of peripheral vision, blurred vision, or permanent blindness allegedly associated with NAION following semaglutide use

Such work could open up new therapeutic avenues (AAAS)

2020;26(9):e3272

A total of 577 patients were randomly assigned (1:1:1) to receive once-weekly dulaglutide (1.5 mg), once-weekly dulaglutide (0.75 mg), or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks